Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | HTR2A | P28223 | 6/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR1D | P28221 | 1/20 | 0.51 |
| ▸ | HTR1B | P28222 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR1E | P28566 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | HTR5A | P47898 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.49 |
| ▸ | PNMT | P11086 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30139650 | 1.00 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| SCHEMBL30139651 | 1.00 | SLC6A4 (0.67) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| Hydrochloric Acid SCHEMBL6076721 | 0.98 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| Hydrochloric Acid SCHEMBL2540387 | 0.96 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| Trifluoroacetic Acid SCHEMBL6257839 | 0.83 | TSHR (0.54) | SLC6A4SLC6A2SLC6A3TSHRSMN1; SMN2 | |
| SCHEMBL14194862 | 0.83 | HTR2A (0.49) | SLC6A4SLC6A2SLC6A3TSHRHTR2A | |
| SCHEMBL8342820 | 0.83 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3TSHRHTR2A | |
| SCHEMBL23583427 | 0.82 | CYP1A2 (0.57) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| SCHEMBL8987672 | 0.81 | L3MBTL1 (0.65) | SLC6A4SLC6A2SLC6A3TSHRIDO1 | |
| SCHEMBL5406572 | 0.81 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3TSHRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | claimed |
| WO-2008100618-A2 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | claimed |
| EP-1377560-B1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LTD (GB) | 2005-09-21 | — | — | EP | claimed |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | claimed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | claimed |
| EP-1377560-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-01-07 | — | — | EP | claimed |
| WO-2002081461-A1 | PIPERAZINE DERIVATIVES AS TACHYKININ ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-10-17 | — | — | WO | claimed |
| EP-1019367-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-07-19 | — | — | EP | claimed |
| WO-1999007672-A1 | DERIVATIVES OF 2,5- AND 3,5-DISUBSTITUTED ANILINES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-02-18 | — | — | WO | claimed |
| WO-2024123663-A1 | ANTIMICROBIAL COMPOUNDS | SRI INTERNATIONAL (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | FUKANG (SHANGHAI) HEALTH TECHNOLOGY CO., LTD (CN) | 2024-01-18 | — | — | US | disclosed |
| EP-3280707-B1 | BICYCLIC QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-12-20 | — | — | EP | disclosed |
| WO-1995035279-A1 | SUBSTITUTED ALKYLDIAMINE DERIVATIVES AND THEIR USE AS TACHYKININ ANTAGONISTS | MERRELL PHARMACEUTICALS INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0589971-A1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 1994-04-06 | — | — | EP | disclosed |
| WO-1992022527-A2 | 3-SUBSTITUTED PYRROLIDINE DERIVATIVES AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | SLC6A4 2513/4885SLC6A2 3349/4885SLC6A3 3674/4885 |
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | SLC6A4 4141/4885SLC6A2 3531/4885SLC6A3 3643/4885 |
| US-20240016775-A1 | ANTI-CORONAVIRUS APPLICATION OF POLY ADP RIBOSE POLYMERASE INHIBITOR | PARP3, PARP1, PARP4 | SLC6A4 2710/4885SLC6A2 4625/4885SLC6A3 3804/4885 |
| US-20040157858-A1 | Piperazine derivatives as tachykinin antagonists | NPSR1, SSTR2, PROKR1 | SLC6A4 269/4885SLC6A2 668/4885SLC6A3 527/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | SLC6A4 4403/4885SLC6A2 4767/4885SLC6A3 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.